Key result
Terazosin treatment for 8 weeks significantly reduced supine (P<0.025) and upright (P<0.01) arterial pressure and blunted cardiovascular pressor responsiveness to norepinephrine.
Why the study?
Does terazosin reduce blood pressure and cardiovascular pressor responsiveness in subjects with mild to moderate essential hypertension?
Population
17 subjects with mild to moderate essential hypertension, mean age 48 +/- 2 years
Comparison
Terazosin treatment for 8 weeks vs 2-week placebo period
Design
Cohort
Follow-up
8 weeks
Authors
Loading...
May lower BP in mild hypertension via alpha-1 blockade; supports mechanism but leaves open randomized outcome trials.
Does terazosin reduce blood pressure and cardiovascular pressor responsiveness in subjects with mild to moderate essential hypertension?
p-value: p=<0.025
Terazosin lowers arterial pressure in essential hypertension by inhibiting alpha 1-mediated, noradrenergic-dependent vasoconstriction without altering sodium concentration or beta-adrenergic mechanisms.
Beretta-Piccoli et al. (1986) studied mild to moderate essential hypertension (n=17). terazosin vs. placebo was evaluated on supine arterial pressure (p=<0.025). Terazosin treatment for 8 weeks significantly reduced supine (P<0.025) and upright (P<0.01) arterial pressure and blunted cardiovascular pressor responsiveness to norepinephrine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: